eMedicine Specialties > Sports Medicine > Hip

Hip Dislocation: Treatment & Medication

Author: Matthew Gammons, MD, Assistant Clinical Professor, Department of Family and Community Medicine, Medical College of Wisconsin; Medical Director, Castleton State College; Consulting Staff, Vermont Orthopaedic Clinic and Killington Medical Clinic
Contributor Information and Disclosures

Updated: Jan 30, 2009

Treatment

Acute Phase

Rehabilitation Program

Physical Therapy

Acutely after successful reduction, resting and icing the hip and taking anti-inflammatory and/or narcotic medications to reduce pain are helpful.

  • For type 1 posterior dislocations, athletes may return to weight bearing as pain allows.
    • Reviews of the literature do not show an increased risk of avascular necrosis with early weight bearing. 
    • Athletes with type 2-5 posterior dislocations and anterior dislocations may require longer times to achieve weight bearing.
  • Hip joints with associated fractures and/or instability are placed in a hip abduction brace postoperatively, which keeps the hip in abduction and slight external rotation for optimal healing, while allowing controlled (limited) flexion and extension. Within 5-7 days of the injury, patients can perform passive range-of-motion exercises with or without assistance in order to maintain normal flexibility (pendulum exercises).

Medical Issues/Complications

Serious complications include sciatic nerve damage, inability to perform closed reduction, and recurring dislocation.

  • The sciatic nerve sits just inferoposterior to the hip joint and is injured in approximately 20% of all hip dislocations. These injuries range from nerve contusion to full laceration. The physician must perform a careful neurologic examination at the time of injury to assess sciatic nerve function. Most sciatic nerve injuries do not warrant acute intervention. Neurologic deficits that occur postreduction warrant immediate surgical intervention to decompress or reconstruct the damaged nerve.
  • Reduction should be attempted as expediently as possible, as prolonged times to reduction are associated with more severe and frequent nerve injuries.14
  • Closed reduction should be attempted under conscious sedation, general anesthesia, or spinal anesthesia immediately after the injury. The inability to perform closed reduction provides evidence for bony fragment involvement in the joint space and/or soft-tissue damage. CT scanning is warranted, followed by excision of loose bodies and open reduction.15
  • The early phase of rehabilitation, involving traction of the injured leg, has been associated with recurring hip dislocation. A successful closed reduction that appears clinically and radiographically stable may redislocate during the first few weeks of the healing process. This dislocation may be caused by a bony fragment or soft-tissue damage that is preventing normal articulation. Perform a CT scan of the hip and discuss surgical intervention.
  • Traumatic subluxation also carries a risk of complications and can be easily missed.  Suspect this injury in patients who have an injury mechanism that is consistent with posterior hip dislocation and painful, limited hip motion. An MRI can be helpful in the diagnosis of this injury.11
  • Anterior dislocations, although less common, have less risk of poor outcomes based on the available data.16

Surgical Intervention

Surgical intervention should be performed if closed reduction is unsuccessful, bony fragments or soft tissue remains in the joint space, or the joint remains unstable. Open reduction is typically performed using a posterior approach, owing to the decreased rate of avascular necrosis relative to the anterior approach.

Thoroughly irrigate the joint to assure adequate cleansing of any loose bone fragments or soft tissue that would prevent proper articulation. Internal fixation of large fracture fragments using screw and plate fixation should be performed by surgeons with experience in managing pelvic fractures.

Hip arthroscopy can be used to remove intraarticular fragments, evaluate intraarticular fractures and chondral injuries, and repair labral tears. When appropriate, hip arthroscopy is preferred to open surgery by those surgeons who are experienced in its use due to its minimally invasive nature, lower morbidity, and quicker recovery.

Consultations

Consult an orthopedic surgeon for any dislocated hip joint. Orthopedic surgeons should be present when attempting a closed reduction. If the closed reduction is unsuccessful, the patient will need to go to the operating room for an open reduction. Usually, keeping an unstable hip reduced with traction while awaiting surgical intervention is helpful (a postreduction hip should be held in traction for 6-8 weeks or until the leg is pain free). A CT scan is typically obtained before proceeding to the operating room.

Recovery Phase

Rehabilitation Program

Physical Therapy
  • Dislocation of the hip joint is an extremely serious injury. The hip joint is crucial for weight bearing and ambulation. Proper rehabilitation must be performed to retain normal musculoskeletal function. Weight bearing with the help of crutches should begin immediately after the patient is pain free and transitioned to full weight bearing as pain allows.
  • Rehabilitation may progress based on the athlete's clinical symptoms, and by 4 weeks, most type 1 hip dislocations can progress to functional weight-bearing exercises, such as shallow squats.
  • An MRI should be considered at week 6 to assess for any signs of femoral head ischemia. 
    • If any evidence of ischemia is present, the athlete should be made partial weight bearing and return to range-of-motion exercises only.
    • If no evidence of femoral head abnormalities is present, the athlete may continue his or her progression.
  • Most athletes with type 1 hip dislocations can return to full activity in 3-4 months. Those with other injuries may require longer time periods to return to sports activity.
  • Cardiovascular activities and stretching exercises are important early in the rehabilitation process to maintain full range of motion about the hip joint. Examples of these activities include upper-extremity cycling, weight training, and floor exercises such as push-ups.

Medical Issues/Complications

A number of chronic complications of hip dislocations can be very severe in nature. These include avascular necrosis, arthritis, chondrolysis, and myositis ossificans.

  • Avascular necrosis is reported in up to 40% of patients because of the disruption of blood supply to the femoral head and from the mechanical force applied to the femoral head during the injury. The risk factor most associated with avascular necrosis is delayed reduction.
    • Generally, the consensus is that reduction should be performed as soon as possible (within 6 hours of injury), and certainly no later than 24 hours after the injury when no appropriate facilities are immediately available.6,12,13 One study found that the risk of avascular necrosis further decreased when reduction was performed within 6 hours of injury.13
    • Avascular necrosis has been diagnosed radiographically from a few months to a few years post injury. Scheduling close follow-up visits every few months is imperative after hip dislocation. Serial radiographs should be taken to evaluate for evidence of avascular necrosis.
    • An MRI of the hip should be considered at 6 weeks after dislocation to assess for the possibility of avascular necrosis of the femoral head.
    • Case reports of late avascular necrosis have been rarely reported; therefore, hip pain in an athlete with a history of dislocation should be investigated regardless of the time interval that has passed.17
  • Arthritis is the most common long-term complication after hip dislocation, affecting up to 50% of all patients. Arthritis is thought to occur from damage to the articular cartilage from traumatic injury. Open reduction has been said to decrease the incidence of postdislocation arthritis, although this is not widely accepted. Radiographs are important for diagnosing arthritis and nonsteroidal anti-inflammatory drugs (NSAIDs) should be prescribed to decrease pain and inflammation in the arthritic hip joint.
  • Myositis ossificans occurs because of muscle and soft-tissue damage after hip dislocation. The rate of this complication is about 2% and is higher in patients who have undergone open reduction. Early closed reduction appears to be the most effective way of preventing myositis ossificans.
  • Another possible complication is a labral tear, which is diagnosed by MRI in the acute setting or MRI arthrogram in the subacute setting. Labral tears are typically treated by hip arthroscopy.

Maintenance Phase

Rehabilitation Program

Physical Therapy

Leg muscle strengthening exercises may begin once the patient is pain free and ambulating without crutches. Patients may work to strengthen the hip flexors, hip extensors, and the muscles nearest the hip, including the quadriceps and hamstrings. Over the next few months, gradually increasing the patient's level of cardiovascular training may be attempted, which should include brisk walking and swimming. Jogging or running may begin at 6-8 weeks but will differ by individual athlete and injury. Full return to sports is generally within 3-4 months.

Other Treatment

  • Imaging
    • X-rays should be repeated at 3 weeks, 6 weeks, 3 months, and 6 months to follow the healing of fractures.
    • An MRI arthrogram should be considered if the athlete develops symptoms with rehabilitation and has negative radiographic findings.

Medication

Patients who have experienced hip dislocation are usually in severe pain. The pain should be evaluated on a scale (0-10) and the patient provided with sufficient analgesia. While in the hospital, intravenous narcotics are the best choice for pain relief. Intravenous morphine (0.1 mg/kg q2-4h) is recommended for optimal analgesia. Postdischarge oral narcotics should be prescribed to keep the patient comfortable at home and during their rehabilitation period. Decreasing the inflammation near the site of injury by giving NSAIDs (eg, ibuprofen, naproxen) every 6 hours is also important. This enables the patient to be as comfortable as possible, while aiding in the healing process.

Analgesics

Pain control is essential to quality patient care. Analgesics ensure patient comfort, promote pulmonary toilet, and have sedating properties, which are beneficial for patients who have sustained trauma or who have sustained injuries.

Related eMedicine topic:
Toxicity, Narcotics


Hydrocodone and acetaminophen (Lorcet, Lortab, Norcet, Vicodin)

Drug combination indicated for moderate to severe pain.

Adult

1-2 tab PO q4-6h prn

Pediatric

<12 years: 10-15 mg/kg/dose acetaminophen PO q4-6h prn; not to exceed 2.6 g/d acetaminophen

>12 years: 750 mg acetaminophen PO q4h; not to exceed 10 mg hydrocodone bitartrate per dose or 5 doses/24h

Coadministration with phenothiazines may decrease analgesic effects; toxicity increases with CNS depressants or tricyclic antidepressants

Documented hypersensitivity; high altitude cerebral edema (HACE) or elevated intracranial pressure (ICP)

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Tablets contain metabisulfite, which may cause hypersensitivity; caution in patients who are dependent on opiates, because this substitution may result in acute opiate-withdrawal symptoms; caution in the presence of severe renal or hepatic dysfunction


Oxycodone and acetaminophen (Percocet, Roxicet, Roxilox, Tylox)

Drug combination indicated for the relief of moderate to severe pain.

Adult

1-2 tab or cap PO q4-6h prn

Pediatric

0.05-0.15 mg/kg/dose oxycodone PO; not to exceed 5 mg/dose of oxycodone q4-6h prn

Phenothiazines may decrease the analgesic effects of this medication; toxicity increases with the coadministration of either CNS depressants or tricyclic antidepressants

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Duration of action may increase in elderly patients; be aware of the total daily dose of acetaminophen the patient is receiving; do not exceed 4,000 mg/24h of acetaminophen; higher doses may cause liver toxicity


Oxycodone and aspirin (Percodan, Roxiprin, Codoxy)

Drug combination indicated for the relief of moderate to severe pain.

Adult

1-2 tab or cap PO q4-6h prn

Pediatric

0.05-0.15 mg/kg/dose oxycodone PO; not to exceed 5 mg/dose of oxycodone q4-6h prn

Phenothiazines may decrease analgesic effects; conversely, toxicity increases when administered concurrently with CNS depressants or tricyclic antidepressants; may also potentiate the anticoagulant effects of warfarin

Documented hypersensitivity; liver damage, hypoprothrombinemia, vitamin K deficiency, bleeding disorders, and asthma; due to association of aspirin with Reye syndrome, do not use in children that have the flu and who are younger than 16 years

Pregnancy

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Duration of action may increase in elderly patients; caution in patients with renal or liver impairment, peptic ulcer disease, and erosive gastritis

Nonsteroidal Anti-inflammatory Drugs (NSAIDs)

NSAIDs have analgesic and antipyretic activities. The mechanism of action of these agents is not known, but NSAIDs may inhibit cyclooxygenase activity and prostaglandin synthesis. Other mechanisms may exist as well, such as inhibition of leukotriene synthesis, lysosomal enzyme release, lipoxygenase activity, neutrophil aggregation, and various cell membrane functions. Treatment of pain tends to be patient specific.

Related eMedicine topic:
Toxicity, Nonsteroidal Anti-inflammatory Agents


Ibuprofen (Ibuprin, Advil, Motrin)

Drug of choice (DOC) for mild to moderate pain. Inhibits inflammatory reactions and pain by decreasing prostaglandin synthesis.

Adult

600-800 mg PO tid prn

Pediatric

10 mg/kg/dose PO q6h

May decrease the effects of loop diuretics with coadministration; coadministration with anticoagulants may increase PT duration (monitor and watch for signs of bleeding); may increase the serum lithium levels and the risk of methotrexate toxicity; probenecid may increase the toxicity of NSAIDs

Documented hypersensitivity to ibuprofen, other NSAIDs, or aspirin; avoid in patients with peptic ulcer disease, recent GI bleeding or perforation, renal insufficiency, and a high risk of bleeding

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Caution in patients with congestive heart failure, hypertension, and decreased renal and hepatic function; caution in the presence of anticoagulation abnormalities or during anticoagulant therapy


Naproxen (Naprelan, Naprosyn, Aleve, Anaprox)

For the relief of mild to moderate pain; inhibits inflammatory reactions and pain by decreasing the activity of cyclooxygenase, which is responsible for prostaglandin synthesis.

Adult

500 mg PO, followed by 250 mg q6-8h; not to exceed 1.25 g/d

Pediatric

<2 years: Not established

>2 years: 2.5 mg/kg/dose PO; not to exceed 10 mg/kg/d

Probenecid may increase the toxicity of NSAIDs; coadministration with ibuprofen may decrease the effects of loop diuretics; coadministration with anticoagulants may prolong PT duration (watch for signs of bleeding); NSAIDs may increase serum lithium levels and the risk of methotrexate toxicity (eg, stomatitis, bone marrow suppression, nephrotoxicity)

Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur; patients with preexisting renal disease or compromised renal perfusion risk acute renal failure; leukopenia occurs rarely, is transient, and usually returns to normal during therapy; persistent leukopenia, granulocytopenia, or thrombocytopenia warrant further evaluation and may require discontinuation of the drug.

More on Hip Dislocation

Overview: Hip Dislocation
Differential Diagnoses & Workup: Hip Dislocation
Treatment & Medication: Hip Dislocation
Follow-up: Hip Dislocation
References

References

  1. Mitchell JC, Giannoudis PV, Millner PA, Smith RM. A rare fracture-dislocation of the hip in a gymnast and review of the literature. Br J Sports Med. Aug 1999;33(4):283-4. [Medline][Full Text].

  2. Rockwood CA, Green DP, Bucholz PW, Heckman JD, eds. Fractures and dislocations of the hip. Fractures in Adults. Vol 2. 4th ed. Philadelphia, Pa: Lippincott-Raven; 1996:1756-1803.

  3. Yates C, Bandy WD, Blasier RD. Traumatic dislocation of the hip in a high school football player. Phys Ther. Jun 2008;88(6):780-8. [Medline].

  4. Liporace FA, Dasti UR, Raiszadeh K. Ipsilateral anterior then irreducible posterior hip dislocation without fracture: a case report. J Orthop Trauma. May-Jun 2008;22(5):363-7. [Medline].

  5. Tennent TD, Chambler AF, Rossouw DJ. Posterior dislocation of the hip while playing basketball. Br J Sports Med. Dec 1998;32(4):342-3. [Medline][Full Text].

  6. Pallia CS, Scott RE, Chao DJ. Traumatic hip dislocation in athletes. Curr Sports Med Rep. Dec 2002;1(6):338-45. [Medline].

  7. Matsumoto K, Sumi H, Sumi Y, Shimizu K. An analysis of hip dislocations among snowboarders and skiers: a 10-year prospective study from 1992 to 2002. J Trauma. Nov 2003;55(5):946-8. [Medline].

  8. Collins J, Trulock S, Chao D. Field management and rehabilitation of an acute posterior hip dislocation in a professional football player. Pro Football Athletic Trainer. Summer 2001;19(1):1,3. [Full Text].

  9. Schmidt GL, Sciulli R, Altman GT. Knee injury in patients experiencing a high-energy traumatic ipsilateral hip dislocation. J Bone Joint Surg Am. Jun 2005;87(6):1200-4. [Medline].

  10. Rancan M, Esser MP, Kossmann T. Irreducible traumatic obturator hip dislocation with subcapital indentation fracture of the femoral neck: a case report. J Trauma. Jun 2007;62(6):E4-6. [Medline].

  11. Cooper DE, Warren RF, Barnes R. Traumatic subluxation of the hip resulting in aseptic necrosis and chondrolysis in a professional football player. Am J Sports Med. May-Jun 1991;19(3):322-4. [Medline].

  12. Yang EC, Cornwall R. Initial treatment of traumatic hip dislocations in the adult. Clin Orthop Relat Res. Aug 2000;377:24-31. [Medline].

  13. Dreinhofer KE, Schwarzkopf SR, Haas NP, Tscherne H. Isolated traumatic dislocation of the hip. Long-term results in 50 patients. J Bone Joint Surg Br. Jan 1994;76(1):6-12. [Medline][Full Text].

  14. Hillyard RF, Fox J. Sciatic nerve injuries associated with traumatic posterior hip dislocations. Am J Emerg Med. Nov 2003;21(7):545-8. [Medline].

  15. Seltzer SE, Weissman BN, Braunstein EM, et al. Indications for CT scanning in orthopedic disorders of hip. Orthop Rev. 1983;12:29-40.

  16. Epstein HC. Posterior fracture-dislocations of the hip: comparison of open and closed methods of treatment in certain types. J Bone Joint Surg Am. Dec 1961;43A:1079-98. [Full Text].

  17. Cash DJ, Nolan JF. Avascular necrosis of the femoral head 8 years after posterior hip dislocation. Injury. Jul 2007;38(7):865-7. [Medline].

  18. Grissom L, Harcke HT, Thacker M. Imaging in the surgical management of developmental dislocation of the hip. Clin Orthop Relat Res. Apr 2008;466(4):791-801. [Medline].

  19. Hartofilakidis G, Yiannakopoulos CK, Babis GC. The morphologic variations of low and high hip dislocation. Clin Orthop Relat Res. Apr 2008;466(4):820-4. [Medline].

  20. Jacob JR, Rao JP, Ciccarelli C. Traumatic dislocation and fracture dislocation of the hip. A long-term follow-up study. Clin Orthop Relat Res. Jan 1987;214:249-63. [Medline].

  21. Kapicioglu MI, Korkusuz F. Diagnosis of developmental dislocation of the hip by sonospectrography. Clin Orthop Relat Res. Apr 2008;466(4):802-8. [Medline].

  22. Kohler R, Seringe R. [Congenital dislocation of the hip: current concepts as a preliminary for diagnosis and treatment] [French]. Rev Chir Orthop Reparatrice Appar Mot. May 2008;94(3):217-227. [Medline].

  23. Pascarella R, Maresca A, Cappuccio M, Reggiani LM, Boriani S. Asymmetrical bilateral traumatic fracture dislocation of the hip: a report of two cases. Chir Organi Mov. May 26 2008;epub ahead of print. [Medline].

  24. Weber M, Ganz R. Recurrent traumatic dislocation of the hip: report of a case and review of the literature. J Orthop Trauma. Jul 1997;11(5):382-5. [Medline].

Further Reading

Keywords

hip dislocation, hip joint, hip fracture, dislocated hip, traumatic hip dislocation, prosthetic hip dislocation, hip dysplasia, congenital hip dislocation, CDH, developmental dysplasia of the hip, DDH, prosthetic hip dislocation, hip fracture-dislocation

Contributor Information and Disclosures

Author

Matthew Gammons, MD, Assistant Clinical Professor, Department of Family and Community Medicine, Medical College of Wisconsin; Medical Director, Castleton State College; Consulting Staff, Vermont Orthopaedic Clinic and Killington Medical Clinic
Matthew Gammons, MD is a member of the following medical societies: American Academy of Family Physicians, American College of Sports Medicine, American Medical Society for Sports Medicine, and American Society of Mechanical Engineers
Disclosure: Nothing to disclose.

Medical Editor

Gerard A Malanga, MD, Founder and Director, New Jersey Sports Medicine Institute; Director of Pain Management, Overlook Hospital; Director of Sports Medicine, Sports Medicine Fellowship Director, Mountainside Hospital; Clinical Chief, Rehabilitation Medicine and Electrodiagnosis, St Michael's Medical Center; Medical Director, Consultant, Horizon Healthcare Worker's Compensation Services, Blue Cross and Blue Shield Worker's Compensation
Gerard A Malanga, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Physical Medicine and Rehabilitation, American College of Sports Medicine, North American Spine Society, and Physiatric Association of Spine, Sports and Occupational Rehabilitation
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

CME Editor

Jon B Whitehurst, MD, Clinical Instructor of Surgery, University of Illinois College of Medicine; Partner and Executive Board Member, Rockford Orthopedic Associates; Orthopedic Chairman, Rockford Memorial Hospital
Jon B Whitehurst, MD is a member of the following medical societies: American Academy of Orthopaedic Surgeons, American Orthopaedic Society for Sports Medicine, and Arthroscopy Association of North America
Disclosure: Nothing to disclose.

Chief Editor

Sherwin SW Ho, MD, Associate Professor, Department of Surgery, Section of Orthopedic Surgery and Rehabilitation Medicine, University of Chicago
Sherwin SW Ho, MD is a member of the following medical societies: American Academy of Orthopaedic Surgeons, American Orthopaedic Society for Sports Medicine, and Arthroscopy Association of North America
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.